These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 1437995)
1. The enantiomers of the valproic acid analogue 2-n-propyl-4-pentynoic acid (4-yn-VPA): asymmetric synthesis and highly stereoselective teratogenicity in mice. Hauck RS; Nau H Pharm Res; 1992 Jul; 9(7):850-5. PubMed ID: 1437995 [TBL] [Abstract][Full Text] [Related]
2. Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid. Hauck RS; Nau H Toxicol Lett; 1989 Oct; 49(1):41-8. PubMed ID: 2510370 [TBL] [Abstract][Full Text] [Related]
3. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Nau H; Hauck RS; Ehlers K Pharmacol Toxicol; 1991 Nov; 69(5):310-21. PubMed ID: 1803343 [TBL] [Abstract][Full Text] [Related]
4. Validation of an in vitro teratology system using chiral substances: stereoselective teratogenicity of 4-yn-valproic acid in cultured mouse embryos. Andrews JE; Ebron-McCoy M; Bojic U; Nau H; Kavlock RJ Toxicol Appl Pharmacol; 1995 Jun; 132(2):310-6. PubMed ID: 7785058 [TBL] [Abstract][Full Text] [Related]
5. Stereoselective dysmorphogenicity of the enantiomers of the valproic acid analogue 2-N-propyl-4-pentynoic acid (4-yn-VPA): cross-species evaluation in whole embryo culture. Andrews JE; Ebron-McCoy MT; Bojic U; Nau H; Kavlock RJ Teratology; 1997 May; 55(5):314-8. PubMed ID: 9261925 [TBL] [Abstract][Full Text] [Related]
6. The enantioselective teratogenicity of 2-n-propyl-4-pentynoic acid (4-yn-VPA) is due to stereoselective intrinsic activity and not differences in pharmacokinetics. Hauck RS; Elmazar MM; Plum C; Nau H Toxicol Lett; 1992 Apr; 60(2):145-53. PubMed ID: 1570629 [TBL] [Abstract][Full Text] [Related]
7. Cell proliferation, migration and CAM-dependent neurite outgrowth as developmental in vitro endpoints for screening teratogenic potential: Application to valproic acid and related analogues of varying potency. Bacon CL; Berezin V; Bode G; Bock E; Bojic U; Doherty P; Ehlers K; Ellerbeck U; Julien P; Kawa A; Maar TE; Nau H; Pirovano R; Regan CM; Schousboe A; Spezia F; Walsh FS; Williams EJ Toxicol In Vitro; 1998 Apr; 12(2):101-9. PubMed ID: 20654391 [TBL] [Abstract][Full Text] [Related]
8. Prediction of embryotoxic effects of valproic acid-derivatives with molecular in vitro methods. Lampen A; Göttlicher M; Nau H ALTEX; 2001; 18(2):123-6. PubMed ID: 11378687 [TBL] [Abstract][Full Text] [Related]
9. S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides. Eikel D; Hoffmann K; Zoll K; Lampen A; Nau H Drug Metab Dispos; 2006 Apr; 34(4):612-20. PubMed ID: 16415118 [TBL] [Abstract][Full Text] [Related]
11. Enantioselective synthesis and preliminary metabolic studies of the optical isomers of 2-n-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproic acid. Porubek DJ; Barnes H; Theodore LJ; Baillie TA Chem Res Toxicol; 1988; 1(6):343-8. PubMed ID: 2979751 [TBL] [Abstract][Full Text] [Related]
12. Prediction of teratogenic potency of valproate analogues using cerebellar aggregation cultures. Maar TE; Ellerbeck U; Bock E; Nau H; Schousboe A; Berezin V Toxicology; 1997 Jan; 116(1-3):159-68. PubMed ID: 9020517 [TBL] [Abstract][Full Text] [Related]
13. Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid. Spiegelstein O; Bialer M; Radatz M; Nau H; Yagen B Chirality; 1999; 11(8):645-50. PubMed ID: 10467316 [TBL] [Abstract][Full Text] [Related]
14. Exencephaly and axial skeletal malformations induced by maternal administration of sodium valproate in the MF1 mouse. Padmanabhan R; Hameed MS J Craniofac Genet Dev Biol; 1994; 14(3):192-205. PubMed ID: 7852547 [TBL] [Abstract][Full Text] [Related]
15. Differential enantioselective effects of pentyl-4-yn-valproate on spatial learning in the rat, and neurite outgrowth and cyclin D3 expression in vitro. O'Loinsigh ED; Gherardini LM; Gallagher HC; Foley AG; Murphy KJ; Regan CM J Neurochem; 2004 Jan; 88(2):370-9. PubMed ID: 14690525 [TBL] [Abstract][Full Text] [Related]
16. The valproic acid metabolite E-2-n-propyl-2-pentenoic acid does not induce spina bifida in the mouse. Ehlers K; Stürje H; Merker HJ; Nau H Dev Pharmacol Ther; 1992; 19(4):196-204. PubMed ID: 1343622 [TBL] [Abstract][Full Text] [Related]
17. Asymmetric synthesis and teratogenic activity of (R)- and (S)-2-ethylhexanoic acid, a metabolite of the plasticizer di-(2-ethylhexyl)phthalate. Hauck RS; Wegner C; Blumtritt P; Fuhrhop JH; Nau H Life Sci; 1990; 46(7):513-8. PubMed ID: 2304384 [TBL] [Abstract][Full Text] [Related]
18. Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity. Gravemann U; Volland J; Nau H Neurotoxicol Teratol; 2008; 30(5):390-4. PubMed ID: 18455366 [TBL] [Abstract][Full Text] [Related]
19. Murine teratology and pharmacokinetics of the enantiomers of sodium 2-ethylhexanoate. Collins MD; Scott WJ; Miller SJ; Evans DA; Nau H Toxicol Appl Pharmacol; 1992 Feb; 112(2):257-65. PubMed ID: 1539163 [TBL] [Abstract][Full Text] [Related]
20. Teratogenic potency of valproate analogues evaluated by quantitative estimation of cellular morphology in vitro. Berezin V; Kawa A; Bojic U; Foley A; Nau H; Regan C; Edvardsen K; Bock E Toxicol In Vitro; 1996 Oct; 10(5):585-94. PubMed ID: 20650240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]